Abstract
The cerebral glucose metabolism of eight patients with schizophrenia and an olfactory agnosia was compared with that of eight normosmic patients with schizophrenia and eight normal controls. Since all patients were scanned while on their current medication regimen, the duration and dosage of the medication of the two patient groups were compared. Similarly, duration and dosage were correlated with absolute regional metabolic rates. No significant effects were found in these analyses. The patients with schizophrenia had significantly lower rates of frontal metabolism than the normal controls. However, the patients with schizophrenia and an olfactory agnosia had a lower right basal ganglia and thalamic metabolism than the normosmic patients with schizophrenia.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Agnosia / diagnostic imaging*
-
Agnosia / drug therapy
-
Agnosia / psychology
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use
-
Blood Glucose / metabolism*
-
Brain / diagnostic imaging
-
Brain / drug effects
-
Brain Mapping
-
Deoxyglucose / analogs & derivatives
-
Deoxyglucose / metabolism
-
Fluorodeoxyglucose F18
-
Humans
-
Male
-
Neurocognitive Disorders / diagnostic imaging*
-
Neurocognitive Disorders / drug therapy
-
Neurocognitive Disorders / psychology
-
Olfactory Pathways / diagnostic imaging
-
Olfactory Pathways / drug effects
-
Schizophrenia / diagnostic imaging*
-
Schizophrenia / drug therapy
-
Schizophrenic Psychology*
-
Tomography, Emission-Computed*
Substances
-
Antipsychotic Agents
-
Blood Glucose
-
Fluorodeoxyglucose F18
-
Deoxyglucose